SCHEDULE 13G/A: Perceptive Advisors Discloses 8.2% Stake in Aldeyra Therapeutics
Beneficial Ownership Disclosure
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a beneficial ownership of 8.2% in Aldeyra Therapeutics, Inc., totaling 4,875,851 common shares.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 12 to Schedule 13G regarding their beneficial ownership in Aldeyra Therapeutics, Inc.
- The Reporting Persons collectively beneficially own 4,875,851 shares of Aldeyra Therapeutics, Inc. Common Stock.
- This ownership represents 8.2% of the outstanding Common Stock of Aldeyra Therapeutics, Inc.
- The percentage is calculated based on 59,708,654 outstanding shares as of February 26, 2025, as reported in the Issuer's Annual Report on Form 10-K filed on February 28, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds the 4,875,851 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors LLC, leading to their deemed beneficial ownership of the same shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: This document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or outlook. It is a regulatory filing providing transparency on ownership structure.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded biotechnology company. It reflects a significant stake held by a specialized life sciences investment firm, which is common in the biotech sector where institutional investment plays a crucial role.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holding (8.2%) by Perceptive Advisors provides transparency regarding the ownership structure and indicates continued institutional interest in Aldeyra Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 2025-02-26 | Date as of which 59,708,654 outstanding shares of Common Stock were reported in the Issuer's Annual Report on Form 10-K. |
| 2025-02-28 | Date Aldeyra Therapeutics, Inc. filed its Annual Report on Form 10-K with the SEC. |
| 2025-04-03 | Date of event which requires filing of this statement (Schedule 13G Amendment No. 12). |
| 2025-04-07 | Signature date of the Schedule 13G filing by the Reporting Persons. |
Keywords
Aldeyra Therapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.